The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

Learn about Rhythm Pharmaceuticals' FDA-approved drug IMCIVREE for obesity, including its potential expansion to children and ...

We recently compiled a list of the 10 Best Japanese Stocks To Buy Now. In this article, we are going to take a look at where ...

We recently published a list of 10 Worst Booming Stocks to Buy According to Short Sellers. In this article, we are going to ...

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.89% of ...

Mirum Pharmaceuticals Inc (MIRM) stock saw a decline, ending the day at $38.96 which represents a decrease of $-0.39 or -0.99% from the prior close of $39.35. The stock opened at $39.46 and touched a ...

Is Syndax Pharmaceuticals, Inc. a buy after the recent stock decline? Analysts support, upcoming approvals, but expect a ...

Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose.

NovaBay shares are trading higher after the company announced it reached a definitive agreement to sell its Avenova assets ...

Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 ...